Valeant inks distribution agreement for Zuacta in Canada
MISSISSAUGA, Ontario — Canadian drug maker Valeant Pharmaceuticals International has signed an agreement with Sanofi’s subsidiary in Canada to distribute a topical medication for osteoarthritis in the country.
Valeant said Tuesday that it had reached an agreement with Sanofi-Aventis Canada for Canadian marketing and distribution rights to Zuacta (zucapsaicin), designed for treating osteoarthritis of the knee.
“Zuacta will be another strong addition to our product portfolio in Canada, where Valeant has an expertise and focus in the area of pain management,” Valeant chairman and CEO J. Michael Pearson said. “Zuacta has already been approved by Health Canada, and we expect to launch this compound in the third quarter of 2011.”
No comments found
Purdue launches RxSafetyMatters.org
STAMFORD, Conn. — Purdue Pharma has launched a new website designed to combat abuse of prescription drugs, the company said Wednesday.
The website, RxSafetyMatters.org, is designed to help healthcare professionals, police and community organizations combat prescription drug diversion and abuse. Purdue is the developer of OxyContin (oxycodone), an extended-release painkiller that is frequently a target of drug abusers.
“Purdue is committed to working with healthcare professionals, law enforcement and local communities to help curb illegal diversion and abuse of medications while also ensuring that these medicines remain available for appropriate medical use,” Purdue president and CEO John Stewart said. “The best chance for making a significant impact on the abuse of prescription drugs is greater collaboration among the many sectors of our society that recognize the serious public health problem that this abuse represents.”
Its time that Purdue put its money into supporting Recovery Programs and paying for the funerals of those who have died due to addiction of opioids that can be traced back to OXY. Working with the healthcare Professionals to whom they pandered the drugs in the first place makes little to NO sense. I do agree that OXYCONTIN has a place, it belongs IN the hospitals, and in Hospice Care. It should ALMOST never be given as a take home script. This MIS-REPRESENTATION of the drug has caused serious addiction problems across the US and has lead to many Deaths... The statement made by John Stewart is too little to late. And it truly shows his lack of commitment to the real problem his company has caused. If he thinks if can be covered up with this collaboration he is sadly mistaken. Re-Marketing the drug for Severe pain only, and pulling it back out of take-home scripts regiment that has brought them BILLIONS of dollars is the ONLY way to stop the endless Tsunami he has created.
FDA committee doesn’t recommend regulatory approval for dapagliflozin
WILMINGTON, Del. — A Food and Drug Administration committee of experts has advised against approving a drug for Type 2 diabetes made by AstraZeneca and Bristol-Myers Squibb, the companies said Tuesday.
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 9-6 against recommending approval for dapagliflozin, saying that data from a two-year clinical trial program that included about 6,000 people did not support the drug’s approval for use in patients along with changes to diet and exercise.
The FDA is not required to follow advisory committee votes but usually does. Shares of AstraZeneca were down about 0.6%, while Bristol’s shares were up about 0.17% Wednesday morning.
No comments found